United States Dermatology Drugs Market Insights 2018-2024: Sales Estimates, Market Share, Market Analysis by Therapeutic Sub-Groups, and Competitor Analysis
US Dermatology Drugs Market Insights - 2019, provides dermatology drugs market analysis, key products, and competitive landscape in the US.
The research includes dermatology drugs market size estimates for 2018 in the US, market size forecast for six years to 2024, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis.
This research helps executives understand the dermatology drugs market landscape in the US. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the US dermatology drugs market.
Highlights of the Research
Dermatology products by Class
Products Launch & Approval by Indication
Phase 3 Clinical Trial Products for Dermatology Indications
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit:
All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...